Adrenomedullin and bronchopulmonary dysplasia / 国际儿科学杂志

ABSTRACT

Bronchopulmonary dysplasia (BPD) is a common respiratory disease in premature infants characterized by alveolar and pulmonary vascular dysplasia.There are currently no effective preventive and therapeutic measures.Adrenomedullin (ADM) is a vasodilator peptide produced by endothelial and smooth muscle cells of the systemic and pulmonary circulation,which promotes alveolar growth and pulmonary angiogenesis.ADM protects the respiratory system through three signaling pathways(1) it promotes pulmonary vascular endothelial cell proliferation through extracellular regulated protein kinases (ERK);(2) attenuates lung cell apoptosis and improves cell proliferation through protein kinase B (PKB) pathway;(3) it down-regulates NADPH oxidase 4 (NOX4) expression in lung tissue to inhibit oxidative stress and improves BPD.So ADM signaling axis may be a potential therapeutic target for human infants with BPD.It provides theoretical basis for clinical prevention and treatment of BPD in premature infants.